The emergence of designed multiple ligands for neurodegenerative disorders.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Progress in neurobiology

• Publication date

  2011-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.pneurobio.2011.04.010PMID 21536094
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ladostigil prevents age-related glial activation and spatial memory deficits in rats.

  2011cited by this paper
• Multifunctional neuroprotective derivatives of rasagiline as anti-alzheimer’s disease drugs

  2011cited by this paper
• Memoquin: A multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer’s disease

  2011cited by this paper
• A step further towards multitarget drugs for Alzheimer and neuronal vascular diseases: targeting the cholinergic system, amyloid-β aggregation and Ca(2+) dyshomeostasis.

  2011cited by this paper
• L-3-n-butylphthalide regulates amyloid precursor protein processing by PKC and MAPK pathways in SK-N-SH cells over-expressing wild type human APP695.

  2011cited by this paper
• Fluorofelbamate

  2011cited by this paper
• The use of multi-target drugs in the treatment of neurodegenerative diseases

  2011cited by this paper
• Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson's disease.

  2011cited by this paper
• Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkins

  2010cited by this paper
• Structure-based design of a thiazolidinedione which targets the mitochondrial protein mitoNEET.

  2010cited by this paper
• A possibility of nutriceuticals as an anti-aging intervention: activation of sirtuins by promoting mammalian NAD biosynthesis.

  2010cited by this paper
• Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy.

  2010cited by this paper
• Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.

  2010cited by this paper
• Amyloid-β-Acetylcholinesterase complexes potentiate neurodegenerative changes induced by the Aβ peptide. Implications for the pathogenesis of Alzheimer's disease

  2010cited by this paper
• Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening.

  2010cited by this paper
• Anti‐inflammatory effects of pioglitazone on iron‐induced oxidative injury in the nigrostriatal dopaminergic system

  2010cited by this paper
• The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action.

  2010cited by this paper
• Rosiglitazone reduces ischaemia-reperfusion injury in patients with the metabolic syndrome.

  2010cited by this paper
• Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial.

  2010cited by this paper
• Sirtuins as Novel Targets for Alzheimer's Disease and Other Neurodegenerative Disorders: Experimental and Genetic Evidence

  2010cited by this paper
• l-3-n-Butylphthalide Improves Cognitive Impairment and Reduces Amyloid-β in a Transgenic Model of Alzheimer's Disease

  2010cited by this paper
• PPARgamma agonist pioglitazone reduces matrix metalloproteinase-9 activity and neuronal damage after focal cerebral ischemia.

  2009cited by this paper
• Protective effects of pioglitazone against global cerebral ischemic-reperfusion injury in gerbils.

  2009cited by this paper
• Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's therapy.

  2009cited by this paper
• Adenosine, adenosine A 2A antagonists, and Parkinson's disease.

  2009cited by this paper
• Cisd2 mediates mitochondrial integrity and life span in mammals

  2009cited by this paper
• Alzheimer's disease: new approaches to drug discovery.

  2009cited by this paper
• Mechanism for resveratrol-induced cardioprotection against reperfusion injury involves glycogen synthase kinase 3beta and mitochondrial permeability transition pore.

  2009cited by this paper
• Adenosine A2A receptors and Parkinson's disease.

  2009cited by this paper
• Ligand-Activated Peroxisome Proliferator–Activated Receptor-γ Protects Against Ischemic Cerebral Infarction and Neuronal Apoptosis by 14-3-3&egr; Upregulation

  2009cited by this paper
• L-3-n-butylphthalide improves cognitive impairment induced by intracerebroventricular infusion of amyloid-beta peptide in rats.

  2009cited by this paper
• Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks.

  2009cited by this paper
• MTDL design strategy in the context of Alzheimer's disease: from lipocrine to memoquin and beyond.

  2009cited by this paper
• A double-blind, delayed-start trial of rasagiline in Parkinson's disease.

  2009cited by this paper
• Acute neuroprotection by pioglitazone after mild brain ischemia without effect on long-term outcome.

  2009cited by this paper
• Structure-activity relationships of memoquin: Influence of the chain chirality in the multi-target mechanism of action.

  2009cited by this paper
• Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinson’s Disease in the UK Setting

  2009cited by this paper
• Amyloid–cholinesterase interactions

  2008cited by this paper
• Pathways of acetylcholine synthesis, transport and release as targets for treatment of adult-onset cognitive dysfunction.

  2008cited by this paper
• Release of acetylcholinesterase (AChE) from beta-amyloid plaques assemblies improves the spatial memory impairments in APP-transgenic mice.

  2008cited by this paper
• A systematic review of off-label uses of memantine for psychiatric disorders.

  2008cited by this paper
• Peroxisome proliferator‐activated receptorsγ (PPARγ) differently modulate the interleukin‐6 expression in the peri‐infarct cortical tissue in the acute and delayed phases of cerebral ischaemia

  2008cited by this paper
• The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity.

  2008cited by this paper
• Multi-target-directed ligands to combat neurodegenerative diseases.

  2008cited by this paper
• l-3-n-Butylphthalide ameliorates beta-amyloid-induced neuronal toxicity in cultured neuronal cells.

  2008cited by this paper
• Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice.

  2008cited by this paper
• The PPARγ agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B

  2008cited by this paper
• The neuroprotective mechanism of action of the multimodal drug ladostigil.

  2008cited by this paper
• Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)

  2008cited by this paper
• Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging.

  2008cited by this paper
• PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms.

  2008cited by this paper
• Drug selection and timing of initiation of treatment in early Parkinson's disease

  2008cited by this paper
• Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin‐induced nigrostriatal dopaminergic degeneration

  2008cited by this paper
• Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders.

  2008cited by this paper
• PPARs in Alzheimer's Disease

  2008cited by this paper
• Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations

  2008cited by this paper
• Neuroprotection in mice by NGP1-01 after transient focal brain ischemia.

  2008cited by this paper
• Antiapoptosis and Mitochondrial Effect of Pioglitazone Preconditioning in the Ischemic/reperfused Heart of Rat

  2008cited by this paper
• Memantine protects rat cortical cultured neurons against β‐amyloid‐induced toxicity by attenuating tau phosphorylation

  2008cited by this paper
• Crystal structure of human mitoNEET reveals distinct groups of iron–sulfur proteins

  2007cited by this paper
• MitoNEET is an iron-containing outer mitochondrial membrane protein that regulates oxidative capacity

  2007cited by this paper
• MitoNEET is a uniquely folded 2Fe–2S outer mitochondrial membrane protein stabilized by pioglitazone

  2007cited by this paper
• The Outer Mitochondrial Membrane Protein mitoNEET Contains a Novel Redox-active 2Fe-2S Cluster*

  2007cited by this paper
• Novel multifunctional anti-Alzheimer drugs with various CNS neurotransmitter targets and neuroprotective moieties.

  2007cited by this paper
• PPAR-gamma: therapeutic target for ischemic stroke.

  2007cited by this paper
• Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.

  2007cited by this paper
• Multi-target therapeutics: when the whole is greater than the sum of the parts.

  2007cited by this paper
• Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease.

  2007cited by this paper
• Monoamine oxidase A and B inhibitors in Parkinson's disease.

  2007cited by this paper
• Induction of Neurotrophic Factors GDNF and BDNF Associated with the Mechanism of Neurorescue Action of Rasagiline and Ladostigil

  2007cited by this paper
• Structure-activity relationships of pentacycloundecylamines at the N-methyl-d-aspartate receptor.

  2007cited by this paper
• PPAR-γ: therapeutic target for ischemic stroke

  2007cited by this paper
• From Symptom Palliation to Disease Modification : Implications for Dementia Care

  2007cited by this paper
• NGP1-01 is a Brain-permeable Dual Blocker of Neuronal Voltage- and Ligand-operated Calcium Channels

  2006cited by this paper
• Adenosine receptors as therapeutic targets

  2006cited by this paper
• Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application.

  2006cited by this paper
• Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion.

  2006cited by this paper
• Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha.

  2006cited by this paper
• PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases.

  2006cited by this paper
• The chemical biology of clinically tolerated NMDA receptor antagonists

  2006cited by this paper
• Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond

  2006cited by this paper
• Designed multiple ligands. An emerging drug discovery paradigm.

  2005cited by this paper
• Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition

  2005cited by this paper
• Combination Inhalers Containing Inhaled Corticosteroids and Long-Acting β2-Agonists: Improved Clinical Efficacy and Dosing Options in Patients with Asthma

  2005cited by this paper
• Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1–42 levels in APPV717I transgenic mice

  2005cited by this paper
• Regulation of Inflammatory Response in Neural Cells in Vitro by Thiadiazolidinones Derivatives through Peroxisome Proliferator-activated Receptor γ Activation*

  2005cited by this paper
• Caffeine improves spatial learning deficits in an animal model of attention deficit hyperactivity disorder (ADHD) -- the spontaneously hypertensive rat (SHR).

  2005cited by this paper
• CNS Targets for multi-functional drugs in the treatment of Alzheimer’s and Parkinson’s diseases

  2005cited by this paper
• Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.

  2005cited by this paper
• Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice.

  2005cited by this paper
• A Peroxisome Proliferator-Activated Receptor-&ggr; Agonist Reduces Infarct Size in Transient but Not in Permanent Ischemia

  2005cited by this paper
• Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons.

  2005cited by this paper
• Caffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats. Involvement of adenosine A1 and A2A receptors.

  2005cited by this paper
• NGP1-01, a lipophilic polycyclic cage amine, is neuroprotective in focal ischemia.

  2005cited by this paper
• Evidence for improved performance in cognitive tasks following selective NR2B NMDA receptor antagonist pre-treatment in the rat

  2005cited by this paper
• Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders.

  2005cited by this paper
• Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.

  2005cited by this paper
• From magic bullets to designed multiple ligands.

  2004cited by this paper
• N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-κB transcription factor

  2004cited by this paper
• Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence.

  2004cited by this paper

• Multi-targeted benzylpiperidine–isatin hybrids: Design, synthesis, biological and in silico evaluation as monoamine oxidases and acetylcholinesterase inhibitors for neurodegenerative disease therapies

  2025cites this paper
• Novel Coumarin–Hydrazone Hybrids as Potential Antiplatelet Agents: Microwave‐Assisted Synthesis, Characterization, In Vitro and In Silico Biological Evaluations and Toxicity Assessment

  2025cites this paper
• A Promising Approach to Target Colorectal Cancer Using Hybrid Triarylmethanes

  2024cites this paper
• Coumarin hybrids for targeted therapies: A promising approach for potential drug candidates

  2024cites this paper
• Targeting PERK and GRP78 in Colorectal Cancer: Genetic Insights and Novel Therapeutic Approaches.

  2024cites this paper
• Coumarin hybrids: a sighting of their roles in drug targeting

  2024cites this paper
• Novel 3-Substituted 8-Methoxycoumarin Derivatives as Anti-Breast Cancer Drugs

  2023cites this paper
• JM-20 affects GABA neurotransmission in Caenorhabditis elegans.

  2022cites this paper
• Develop potential multi-target drugs by self-assembly of quercetin with amino acids and metal ion to achieve significant efficacy in anti-Alzheimer’s disease

  2022cites this paper
• Ameliorating potential of curcumin and its analogue in central nervous system disorders and related conditions: A review of molecular pathways

  2022cites this paper
• Novel brain-targeting 3-n-butylphthalide prodrugs for ischemic stroke treatment.

  2021cites this paper
• NEET proteins as novel drug targets for mitochondrial dysfunction

  2021cites this paper
• Dual monoamine oxidase B and acetylcholine esterase inhibitors for treating movement and cognition deficits in a C. elegans model of Parkinson’s disease

  2021cites this paper
• Piperazine-substituted chalcones: a new class of MAO-B, AChE, and BACE-1 inhibitors for the treatment of neurological disorders

  2021cites this paper
• Selected Class of Enamides Bearing Nitro Functionality as Dual-Acting with Highly Selective Monoamine Oxidase-B and BACE1 Inhibitors

  2021cites this paper
• Potentiating the Benefits of Melatonin through Chemical Functionalization: Possible Impact on Multifactorial Neurodegenerative Disorders

  2021cites this paper
• A balancing act: using small molecules for therapeutic intervention of the p53 pathway in cancer.

  2020cites this paper
• Selected 1,3‐Benzodioxine‐Containing Chalcones as Multipotent Oxidase and Acetylcholinesterase Inhibitors

  2020cites this paper
• Lead discovery of a guanidinyl tryptophan derivative on amyloid cascade inhibition

  2020cites this paper
• Synthetic Strategies and Biological Potential of Coumarin-Chalcone Hybrids: A New Dimension to Drug Design

  2020cites this paper
• Hybrids of Coumarin Derivatives as potent and multifunctional bioactive agents: A review.

  2020cites this paper
• JM-20, a novel hybrid molecule, protects against rotenone-induced neurotoxicity in experimental model of Parkinson's disease.

  2019cites this paper
• Design, Synthesis, Anti-Proliferative Evaluation and Cell Cycle Analysis of Hybrid 2-Quinolones

  2019cites this paper
• Ethoxylated Head of Chalcones as a New Class of Multi‐Targeted MAO Inhibitors

  2019cites this paper
• The current status of pharmacotherapy for the treatment of Parkinson's disease: transition from single-target to multitarget therapy.

  2019cites this paper
• Co-crystals as a new approach to multimodal analgesia and the treatment of pain

  2019cites this paper
• Emerging therapeutic potentials of dual‐acting MAO and AChE inhibitors in Alzheimer's and Parkinson's diseases

  2019cites this paper
• Spondias mombim L. (Anacardiaceae): Chemical fingerprints, inhibitory activities, and molecular docking on key enzymes relevant to erectile dysfunction and Alzheimer's diseases.

  2019cites this paper
• Ameliorative effect of Nauclia latifolia leaf extract on valproic acid -induced neurotoxicity in oxidative stress rats: Role of p53 and S100B

  2019cites this paper
• Multifunctional Compounds for Activation of the p53-Y220C Mutant in Cancer.

  2018cites this paper
• Phenolic Constituents and Inhibitory Effects of Hibiscus sabdariffa L. (Sorrel) Calyx on Cholinergic, Monoaminergic, and Purinergic Enzyme Activities

  2018influential citation
• From folk medicine to functional food: a review on the bioactive components and pharmacological properties of citrus peels

  2018cites this paper
• Inhibitory effect of ethyl acetate fraction of Solanum macrocarpon L. leaves on cholinergic, monoaminergic, and purinergic enzyme activities

  2018cites this paper
• The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer's disease.

  2018cites this paper
• Synthesis and evaluation of new designed multiple ligands directed towards both peroxisome proliferator-activated receptor-γ and angiotensin II type 1 receptor.

  2018cites this paper
• Design, synthesis and evaluation of indole derivatives as multifunctional agents against Alzheimer's disease.

  2018cites this paper
• The potent neuroprotective activities and underlying molecular mechanisms by T-006 : a novel anti-alzheimer's agent derived from Chinese medicine

  2017cites this paper
• An Overview of Multifunctional Metal Chelators as Potential Treatments for Neurodegenerative Diseases

  2017cites this paper
• Dual inhibitors of cholinesterases and monoamine oxidases for Alzheimer's disease.

  2017cites this paper
• One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke

  2017cites this paper
• Polycyclic compounds as carriers for neuroactive non- steroidal anti-inflammatory drugs

  2017cites this paper
• Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration

  2016influential citation
• Naturally Inspired Molecules as Multifunctional Agents for Alzheimer’s Disease Treatment

  2016cites this paper
• Drug discovery of neurodegenerative disease through network pharmacology approach in herbs.

  2016cites this paper
• Pharmacophore generation, atom-based 3D-QSAR, HQSAR and activity cliff analyses of benzothiazine and deazaxanthine derivatives as dual A2A antagonists/MAO‑B inhibitors

  2016cites this paper
• Synthesis and Biological Evaluation of Pentacycloundecylamines and Triquinylamines as Voltage‐Gated Calcium Channel Blockers

  2016cites this paper
• Aminobenzimidazoles and Structural Isomers as Templates for Dual‐Acting Butyrylcholinesterase Inhibitors and hCB2R Ligands To Combat Neurodegenerative Disorders

  2016cites this paper
• Neuroprotection against glutamate-induced excitotoxicity and induction of neurite outgrowth by T-006, a novel multifunctional derivative of tetramethylpyrazine in neuronal cell models.

  2016cites this paper
• Alkaloid extracts from shea butter and breadfruit as potential inhibitors of monoamine oxidase, cholinesterases, and lipid peroxidation in rats’ brain homogenates: a comparative study

  2016cites this paper
• Combining in vitro and in silico approaches to evaluate the multifunctional profile of rosmarinic acid from Blechnum brasiliense on targets related to neurodegeneration.

  2016cites this paper
• Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders.

  2016cites this paper
• From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimer's Disease.

  2015cites this paper
• Protection from neurodegeneration in the 6-hydroxydopamine (6-OHDA) model of Parkinson's with novel 1-hydroxypyridin-2-one metal chelators.

  2015cites this paper
• 3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3β Fragment Hits against Alzheimer's Disease.

  2015cites this paper
• Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids.

  2015cites this paper
• First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models.

  2015cites this paper
• Structure-based development of nitroxoline derivatives as potential multifunctional anti-Alzheimer agents.

  2015cites this paper
• Multitarget ligands and theranostics: sharpening the medicinal chemistry sword against prion diseases.

  2014cites this paper
• Identification of novel scaffolds for Monoamine oxidase B inhibitors

  2014influential citation
• Multifunctional compounds: smart molecules for multifactorial diseases.

  2014cites this paper
• First-in-class thyrotropin-releasing hormone ( TRH )-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models

  2014cites this paper
• Coumarin hybrids as novel therapeutic agents.

  2014cites this paper
• Design, synthesis and evaluation of seleno-dihydropyrimidinones as potential multi-targeted therapeutics for Alzheimer's disease.

  2014cites this paper
• Alkaloids from Psychotria Target Sirtuins: In Silico and In Vitro Interaction Studies

  2014cites this paper
• A novel multi-target ligand (JM-20) protects mitochondrial integrity, inhibits brain excitatory amino acid release and reduces cerebral ischemia injury in vitro and in vivo.

  2014cites this paper
• Monoamine oxidase A and B substrates: probing the pathway for drug development.

  2014cites this paper
• Indole alkaloids and semisynthetic indole derivatives as multifunctional scaffolds aiming the inhibition of enzymes related to neurodegenerative diseases--a focus on Psychotria L. Genus.

  2014cites this paper
• Neuroprotective Effects of Bis(7)-tacrine in a Rat Model of Pressure-Induced Retinal Ischemia

  2014cites this paper
• Interdisciplinary Chemical Approaches for Neuropathology

  2014cites this paper
• Computational Approaches To Anti-Toxin Therapies And Biomarker Identification

  2013cites this paper
• Triquinane scaffolds: Shape and geometry as a function of saturation and bridgehead groups

  2013cites this paper
• Novel adamantane derivatives as multifunctional neuroprotective agents

  2013influential citation
• Synthesis of (E)-8-(3-chlorostyryl)caffeine analogues leading to 9-deazaxanthine derivatives as dual A(2A) antagonists/MAO-B inhibitors.

  2013cites this paper
• Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders

  2013cites this paper
• Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.

  2013cites this paper
• Multi-target compounds acting in the central nervous system designed from natural products.

  2013cites this paper
• Insights into the structural biology of G-protein coupled receptors impacts drug design for central nervous system neurodegenerative processes

  2013cites this paper
• Rationally designed multi-targeted agents against neurodegenerative diseases.

  2013cites this paper
• A SYNTHETIC APPROACH TOWARDS NOVEL SERIES OF 3-(3-(1-PIPERAZINYL)PROPYL -1H-INDOLE DERIVATIVES AS MONOAMINERGIC MULTI-TARGET AGENTS. DOCKING STUDIES AND PHARMACOLOGICAL EVALUATION AT SERT, D2, AND MAO-A RECEPTORS.

  2013cites this paper
• Indole alkaloids of Psychotria as multifunctional cholinesterases and monoamine oxidases inhibitors.

  2013cites this paper
• Monoamine oxidases: the biochemistry of the proteins as targets in medicinal chemistry and drug discovery.

  2012cites this paper
• Rationale for the use of multifunctional drugs as neuroprotective agents for glaucoma

  2012cites this paper
• Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis

  2012cites this paper
• Designed multiple ligands: basic research vs clinical outcomes.

  2012cites this paper
• From Anti-Parkinson's Drug Rasagiline to Novel Multitarget Iron Chelators with Acetylcholinesterase and Monoamine Oxidase Inhibitory and Neuroprotective Properties for Alzheimer's Disease

  2012cites this paper
• Synthesis of Stable Genipin Derivatives and Studies of Their Neuroprotective Activity in PC12 Cells

  2012cites this paper
• Oxidative Stress in Neurodegenerative Diseases: Mechanisms and Therapeutic Perspectives

  2011influential citation
• Multifunctional drugs as novel antidotes for organophosphates' poisoning.

  2011cites this paper
• Identification of modulators of ataxin-3 proteotoxicity in animal models of Machado-Joseph disease

  2011cites this paper
• Synthesis of monomeric derivatives to probe memoquin's bivalent interactions.

  2011cites this paper